Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein - PubMed (original) (raw)

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

I Hara et al. J Exp Med. 1995.

Abstract

The immune system can recognize differentiation antigens that are selectively expressed on malignant cells and their normal cell counterparts. However, it is uncertain whether immunity to differentiation antigens can effectively lead to tumor rejection. The mouse brown locus protein, gp75 or tyrosinase-related protein 1, is a melanocyte differentiation antigen expressed by melanomas and normal melanocytes. The gp75 antigen is recognized by autoantibodies and autoreactive T cells in persons with melanoma. To model autoimmunity against a melanocyte differentiation antigen, mouse antibodies against gp75 were passively transferred into tumor-bearing mice. Passive immunization with a mouse monoclonal antibody against gp75 induced protection and rejection of both subcutaneous tumors and lung metastases in syngeneic C57BL/6 mice, including established tumors. Passive immunity produced coat color alterations but only in regenerating hairs. This system provides a model for autoimmune vitiligo and shows that immune responses to melanocyte differentiation antigens can influence mouse coat color. Immune recognition of a melanocyte differentiation antigen can reject tumors, providing a basis for targeting tissue autoantigens expressed on cancer.

PubMed Disclaimer

Similar articles

• Tumor immunity and autoimmunity induced by immunization with homologous DNA.
  Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Weber LW, et al. J Clin Invest. 1998 Sep 15;102(6):1258-64. doi: 10.1172/JCI4004. J Clin Invest. 1998. PMID: 9739060 Free PMC article.
• Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.
  Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Naftzger C, et al. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14809-14. doi: 10.1073/pnas.93.25.14809. Proc Natl Acad Sci U S A. 1996. PMID: 8962137 Free PMC article.
• Coupling and uncoupling of tumor immunity and autoimmunity.
  Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN. Bowne WB, et al. J Exp Med. 1999 Dec 6;190(11):1717-22. doi: 10.1084/jem.190.11.1717. J Exp Med. 1999. PMID: 10587362 Free PMC article.
• Multiple pathways to tumor immunity and concomitant autoimmunity.
  Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Turk MJ, et al. Immunol Rev. 2002 Oct;188:122-35. doi: 10.1034/j.1600-065x.2002.18811.x. Immunol Rev. 2002. PMID: 12445286 Review.
• Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
  Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Engelhard VH, et al. Immunol Rev. 2002 Oct;188:136-46. doi: 10.1034/j.1600-065x.2002.18812.x. Immunol Rev. 2002. PMID: 12445287 Review.

Cited by

• Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
  Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD. Lesokhin AM, et al. Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15. Cancer Res. 2012. PMID: 22174368 Free PMC article.
• Melanoma and Vitiligo: In Good Company.
  Failla CM, Carbone ML, Fortes C, Pagnanelli G, D'Atri S. Failla CM, et al. Int J Mol Sci. 2019 Nov 15;20(22):5731. doi: 10.3390/ijms20225731. Int J Mol Sci. 2019. PMID: 31731645 Free PMC article. Review.
• Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
  Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD. Cohen AD, et al. PLoS One. 2010 May 3;5(5):e10436. doi: 10.1371/journal.pone.0010436. PLoS One. 2010. PMID: 20454651 Free PMC article.
• Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
  Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M. Valmori D, et al. Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52. doi: 10.1073/pnas.0703395104. Epub 2007 May 15. Proc Natl Acad Sci U S A. 2007. PMID: 17517626 Free PMC article.
• Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition.
  Zhou P, Fang X, McNally BA, Yu P, Zhu M, Fu YX, Wang L, Liu Y, Zheng P. Zhou P, et al. Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17134-9. doi: 10.1073/pnas.0905707106. Epub 2009 Sep 23. Proc Natl Acad Sci U S A. 2009. PMID: 19805094 Free PMC article.

References

1. 1. J Exp Med. 1995 Feb 1;181(2):799-804 - PubMed
2. 1. Lancet. 1994 Oct 15;344(8929):1049-52 - PubMed
3. 1. J Exp Med. 1982 Dec 1;156(6):1755-66 - PubMed
4. 1. J Exp Med. 1982 Dec 1;156(6):1884-9 - PubMed
5. 1. J Exp Med. 1983 Jul 1;158(1):246-51 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program